134 related articles for article (PubMed ID: 38385294)
1. Selective pharmacologic targeting of CTPS1 shows single-agent activity and synergizes with BCL2 inhibition in aggressive mantle cell lymphoma.
Durand R; Bellanger C; Kervoëlen C; Tessoulin B; Dousset C; Menoret E; Asnagli H; Parker A; Beer P; Pellat-Deceunynck C; Chiron D
Haematologica; 2024 Feb; ():. PubMed ID: 38385294
[TBL] [Abstract][Full Text] [Related]
2. CTPS1 is a novel therapeutic target in multiple myeloma which synergizes with inhibition of CHEK1, ATR or WEE1.
Pfeiffer C; Grandits AM; Asnagli H; Schneller A; Huber J; Zojer N; Schreder M; Parker AE; Bolomsky A; Beer PA; Ludwig H
Leukemia; 2024 Jan; 38(1):181-192. PubMed ID: 37898670
[TBL] [Abstract][Full Text] [Related]
3. Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal
Prukova D; Andera L; Nahacka Z; Karolova J; Svaton M; Klanova M; Havranek O; Soukup J; Svobodova K; Zemanova Z; Tuskova D; Pokorna E; Helman K; Forsterova K; Pacheco-Blanco M; Vockova P; Berkova A; Fronkova E; Trneny M; Klener P
Clin Cancer Res; 2019 Jul; 25(14):4455-4465. PubMed ID: 31004002
[TBL] [Abstract][Full Text] [Related]
4. CTP Synthase 1 Is a Novel Therapeutic Target in Lymphoma.
Asnagli H; Minet N; Pfeiffer C; Hoeben E; Lane R; Laughton D; Birch L; Jones G; Novak A; Parker AE; Ludwig H; Fischer A; Latour S; Beer PA
Hemasphere; 2023 Apr; 7(4):e864. PubMed ID: 37008165
[TBL] [Abstract][Full Text] [Related]
5. MYC-induced cytidine metabolism regulates survival and drug resistance via cGas-STING pathway in mantle cell lymphoma.
Liang JH; Ren YM; Du KX; Gao R; Duan ZW; Guo JR; Xing TY; Wang WT; Wang L; Wang Y; Wang R; Li JY; Xu W
Br J Haematol; 2023 Aug; 202(3):550-565. PubMed ID: 37226519
[TBL] [Abstract][Full Text] [Related]
6. Cyclin dependent kinase 4/6 inhibitor palbociclib synergizes with BCL2 inhibitor venetoclax in experimental models of mantle cell lymphoma without RB1 deletion.
Malarikova D; Jorda R; Kupcova K; Senavova J; Dolnikova A; Pokorna E; Kazantsev D; Nozickova K; Sovilj D; Bellanger C; Chiron D; Andera L; Krystof V; Strnad M; Helman K; Klanova M; Trneny M; Havranek O; Klener P
Exp Hematol Oncol; 2024 Mar; 13(1):34. PubMed ID: 38528594
[TBL] [Abstract][Full Text] [Related]
7. The Therapeutic Synergy of Selinexor and Venetoclax in Mantle Cell Lymphoma Through Induction of DNA Damage and Perturbation of the DNA Damage Response.
Yuan S; Zuo W; Liu T; Fu H
Technol Cancer Res Treat; 2023; 22():15330338231208608. PubMed ID: 37880950
[No Abstract] [Full Text] [Related]
8. PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine.
Arribas AJ; Gaudio E; Napoli S; Yvon Herbaux CJ; Tarantelli C; Bordone RP; Cascione L; Munz N; Aresu L; Sgrignani J; Rinaldi A; Kwee I; Rossi D; Cavalli A; Zucca E; Stussi G; Stathis A; Sloss C; Davids MS; Bertoni F
bioRxiv; 2023 Nov; ():. PubMed ID: 38014209
[TBL] [Abstract][Full Text] [Related]
9. Structural basis for isoform-specific inhibition of human CTPS1.
Lynch EM; DiMattia MA; Albanese S; van Zundert GCP; Hansen JM; Quispe JD; Kennedy MA; Verras A; Borrelli K; Toms AV; Kaila N; Kreutter KD; McElwee JJ; Kollman JM
Proc Natl Acad Sci U S A; 2021 Oct; 118(40):. PubMed ID: 34583994
[TBL] [Abstract][Full Text] [Related]
10. Differential roles of CTP synthetases CTPS1 and CTPS2 in cell proliferation.
Minet N; Boschat AC; Lane R; Laughton D; Beer P; Asnagli H; Soudais C; Bourne T; Fischer A; Martin E; Latour S
Life Sci Alliance; 2023 Sep; 6(9):. PubMed ID: 37348953
[TBL] [Abstract][Full Text] [Related]
11. CTP synthase 1 deficiency in humans reveals its central role in lymphocyte proliferation.
Martin E; Palmic N; Sanquer S; Lenoir C; Hauck F; Mongellaz C; Fabrega S; Nitschké P; Esposti MD; Schwartzentruber J; Taylor N; Majewski J; Jabado N; Wynn RF; Picard C; Fischer A; Arkwright PD; Latour S
Nature; 2014 Jun; 510(7504):288-92. PubMed ID: 24870241
[TBL] [Abstract][Full Text] [Related]
12. PIK-75 overcomes venetoclax resistance
Huang S; Liu Y; Chen Z; Wang M; Jiang VC
Am J Cancer Res; 2022; 12(3):1102-1115. PubMed ID: 35411248
[TBL] [Abstract][Full Text] [Related]
13. CTP synthase 1, a smooth muscle-sensitive therapeutic target for effective vascular repair.
Tang R; Cui XB; Wang JN; Chen SY
Arterioscler Thromb Vasc Biol; 2013 Oct; 33(10):2336-44. PubMed ID: 24008161
[TBL] [Abstract][Full Text] [Related]
14. Impaired lymphocyte function and differentiation in CTPS1-deficient patients result from a hypomorphic homozygous mutation.
Martin E; Minet N; Boschat AC; Sanquer S; Sobrino S; Lenoir C; de Villartay JP; Leite-de-Moraes M; Picard C; Soudais C; Bourne T; Hambleton S; Hughes SM; Wynn RF; Briggs TA; ; Patel S; Lawrence MG; Fischer A; Arkwright PD; Latour S
JCI Insight; 2020 Mar; 5(5):. PubMed ID: 32161190
[TBL] [Abstract][Full Text] [Related]
15. Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents.
Deng M; Xu-Monette ZY; Pham LV; Wang X; Tzankov A; Fang X; Zhu F; Visco C; Bhagat G; Dybkaer K; Chiu A; Tam W; Zu Y; Hsi ED; You H; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Parsons BM; Hagemeister F; van Krieken JH; Piris MA; Winter JN; Li Y; Xu B; Liu P; Young KH
Mol Cancer Res; 2021 Feb; 19(2):249-260. PubMed ID: 33154093
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of cyclin-dependent kinase 9 synergistically enhances venetoclax activity in mantle cell lymphoma.
Zhao X; Bodo J; Chen R; Durkin L; Souers AJ; Phillips DC; Hsi ED
EJHaem; 2020 Jul; 1(1):161-169. PubMed ID: 35847704
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients.
Zhao S; Kanagal-Shamanna R; Navsaria L; Ok CY; Zhang S; Nomie K; Han G; Hao D; Hill HA; Jiang C; Yao Y; Nastoupil L; Westin J; Fayad L; Nair R; Steiner R; Ahmed S; Samaniego F; Iyer SP; Oriabure O; Chen W; Song X; Zhang J; Badillo M; Moghrabi O; Aranda J; Tang G; Yin CC; Patel K; Medeiros LJ; Li S; Vega F; Thirumurthi S; Xu G; Neelapu S; Flowers CR; Romaguera J; Fowler N; Wang L; Wang ML; Jain P
Am J Hematol; 2020 Jun; 95(6):623-629. PubMed ID: 32239765
[TBL] [Abstract][Full Text] [Related]
18. Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas.
Pham LV; Huang S; Zhang H; Zhang J; Bell T; Zhou S; Pogue E; Ding Z; Lam L; Westin J; Davis RE; Young KH; Medeiros LJ; Ford RJ; Nomie K; Zhang L; Wang M
Clin Cancer Res; 2018 Aug; 24(16):3967-3980. PubMed ID: 29666304
[No Abstract] [Full Text] [Related]
19. Epstein-Barr Virus Induced Cytidine Metabolism Roles in Transformed B-Cell Growth and Survival.
Liang JH; Wang C; Yiu SPT; Zhao B; Guo R; Gewurz BE
mBio; 2021 Aug; 12(4):e0153021. PubMed ID: 34281398
[TBL] [Abstract][Full Text] [Related]
20. The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma.
Li J; Wang X; Xie Y; Ying Z; Liu W; Ping L; Zhang C; Pan Z; Ding N; Song Y; Zhu J
Int J Cancer; 2018 Jan; 142(1):202-213. PubMed ID: 28905990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
